Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial: A randomized clinical trial of neoadjuvant therapy for ESCC

BACKGROUND: A Phase II study was undertaken to evaluate the safety and efficacy of the neoadjuvant socazolimab, a novel PD-L1 inhibitor, in combination with nab-paclitaxel and cisplatin for locally advanced esophageal squamous cell carcinoma (ESCC). METHODS: Sixty-four patients were randomly divided...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yong, Zhou, Aiping, Liu, Shuoyan, He, Ming, Chen, Keneng, Tian, Ziqiang, Li, Yin, Qin, Jianjun, Wang, Zhen, Chen, Haiquan, Tian, Hui, Yu, Yue, Qu, Wang, Xue, Liyan, He, Shun, Wang, Shuhang, Bie, Fenglong, Bai, Guangyu, Zhou, Bolun, Yang, Zhaoyang, Huang, Huiyao, Fang, Yan, Li, Benjamin, Dai, Xiangrong, Gao, Shugeng, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993718/
https://www.ncbi.nlm.nih.gov/pubmed/36882775
http://dx.doi.org/10.1186/s12916-023-02804-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993718/
https://www.ncbi.nlm.nih.gov/pubmed/36882775
http://dx.doi.org/10.1186/s12916-023-02804-y

Ejemplares similares